Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Sometimes – for no obvious reason – there is a flurry of publications from a particular area which has been quiet for a long time. RSV is such an area where new drug development had a hard time getting started. There was always the lure of big money: an infection Continue reading There is Momentum Building for RSV Therapeutics
Whatever has become of investigative journalism? All we read after the Stifel conference call (11/17/2015) is descriptive rehash of information provided by Tetraphase at the conference. No probing questions that we thought investors would ask who just lost 80% of their money. No signs of analytical or strategic readjustment at Continue reading Eravacycline Conference Call: Unrevealing and Disappointing
At the recent AMDAC, the frequent mention of an unusual uUTI study caught my attention. In their review of placebo-controlled trials, FDA mentioned a study comparing ciprofloxacin with Ibuprofen (Motrin), an NSAID drug without any antibacterial activity[1]. By the outcome of total symptom relief, there was no difference. Obviously, there Continue reading Ibuprofen For uUTI: Interesting Pilot Trial But More to Come Soon